ASCO 2020 Ovarian Cancer In Depth

ASCO 2020 Ovarian Cancer In-Depth

FDA analyses find trial-to-trial variation in the analysis of patient reported outcomes, underscoring the need for standardization.

Tyrer-Cuzick Breast Cancer Model Well-Calibrated Among Most Races/Ethnicities

The TC model uses various parameters to predict risk such as genetic risk and nonfamilial factors including personal, hormonal, and lifestyle characteristics.

KEYNOTE-100: Pembrolizumab Had Modest Activity in Recurrent Advanced Ovarian Cancer

Analysis of biomarkers to predict response to pembrolizumab are ongoing.

A retrospective study showed improved survival among patients with ovarian cancer treated with beta-

Olaparib/Cediranib Combination Is Not Superior to Standard of Care in Recurrent Ovarian Cancer

Overall survival data are not currently mature. However, at the time of this analysis no difference in overall survival was observed between the 3 treatment arms.

Synchronous metastatic disease is characterized by the presence of metastatic lesions, in addition to the primary tumor, at diagnosis.

Secondary Cytoreductive Surgery Extended PFS in Recurrent Ovarian Cancer

A longer treatment-free survival interval associated with surgery may contribute to overall survival.

Birth Rates After ART Not Significantly Different Among Female Cancer Survivors, Siblings

The researchers found that patients who received pelvic radiation had a decreased chance of live birth.

Double mutants may predict resistance to PARP inhibitors and could also indicate sensitivity to alte

Mirvetuximab Soravtansine Plus Bevacizumab in FRα-Overexpressing Advanced Epithelial Ovarian Cancer

This study evaluated the combination of bevacizumab with an antibody drug conjugate targeted to the folate receptor alpha in the setting of epithelial ovarian cancer.

Next post in ASCO 2020 Ovarian Cancer In-Depth

ASCO 2020 Ovarian Cancer In Depth